Hepatitis Test Solution/Diagnosis Market

Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, Nursing Homes) - Global Forecast to 2023

Report Code: MD 6643 Oct, 2018, by marketsandmarkets.com

[112 Pages Report] Hepatitis testing refers to the diagnostic procedures performed to determine what genotype of hepatitis is causing the disease and what treatment is best suited. As different hepatitis viruses cause similar symptoms, it is important to run a series of diagnostic tests to identify the virus. The global hepatitis test solution/diagnosis market is valued at 2.54 billion in 2017 and expected to grow at CAGR of 4.9% to USD 3.37 billion by 2023 during the forecast period. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023.

Research Methodology

Top-down and bottom-up approaches were used to validate the size of the global hepatitis test solution/diagnosis market and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary research, and their market revenues were determined through primary and secondary research. Secondary sources include annual reports, press releases, and investor presentations of companies; white papers; medical journals; certified publications; articles from recognized authors; gold standard and silver standard websites; directories; and databases. In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as to assess future prospects.

This data is consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report. Some of the secondary resources referred to are World Health Organization (WHO), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), US FDA, Parenteral Drug Association (PDA), International Society for Pharmaceutical Engineering (ISPE), and Washington Biotechnology & Biomedical Association (WBBA)

Hepatitis Test Solution/Diagnosis Market

To know about the assumptions considered for the study, download the pdf brochure

The key players in the hepatitis test solution/diagnosis market are Roche (Switzerland), Abbott Laboratories (US), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), Danaher (US), bioMérieux (France), and Grifols (Spain).

Target Audience:

  • Blood banks
  • Pathologists and pathology laboratories
  • Distributors of IVD products
  • Research institutes
  • Hospitals and clinics
  • Healthcare institutions
  • Group purchasing organizations (GPOs)
  • Market research and consulting firms

Scope of the Report

The research report categorizes the global hepatitis test solution/diagnosis market into the following segments and subsegments:

Hepatitis test solution/diagnosis Market, by Disease type

  • Hepatitis B
  • Hepatitis C
  • Other Disease type

Hepatitis test solution/diagnosis Market, by Technology

  • ELISA
  • Rapid Diagnostics test
  • PCR
  • INAAT
  • Other Technologies

Hepatitis test solution/diagnosis Market, by End User

  • Hospitals & Diagnostics Labs
  • Blood Banks
  • Other end user

Hepatitis test solution/diagnosis Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • RoE
  • Asia Pacific (APAC)
  • Rest of the World (RoW)

Available customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the APAC hepatitis test solution/diagnosis market — China, Japan, India, and others

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

The global hepatitis test solution/diagnosis market is projected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, at a CAGR of 4.9% during the forecast period. This market is primarily driven by factors such as the high burden of hepatitis worldwide, increasing number of blood transfusions and donations, benefits offered by PoC instruments & kits, and awareness initiatives. Emerging markets such as China, India, Brazil, and Africa are expected to offer lucrative growth opportunities for the players in this market. However, the high cost of NAT tests and a lack of mandate for NAT in developing countries are expected to restrain the growth of this market during the forecast period.

The ELISA segment is expected to account for the largest share of the global hepatitis test solution/diagnosis market, by technology. The large share of ELISA is mainly driven by the wide acceptance of this test in clinical practices to diagnose hepatitis. Rapid diagnostics test segment is expected to register the highest CAGR during the forecast period. High growth of rapid diagnostics test segment can be attributed to the low cost of this test type, its high analytical sensitivity, and its ability to detect all known 11 subtypes of HBsAg.

The hospital and diagnostics laboratories segment is expected to account for the largest share of hepatitis test solution/diagnosis market, by end user, in 2018 and is expected to register the highest CAGR during the forecast period. This can primarily be attributed to the growing patient population, increase in Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests.

Hepatitis Test Solution/Diagnosis Market

Geographically, the hepatitis test solution/diagnosis market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018 North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market. The large share of the North America region is mainly attributed to factors such as the developed healthcare systems in the US and Canada, rising adoption of advanced technologies, and the presence of a large number of leading national clinical laboratories.

The APAC region is projected to grow at the highest CAGR during the forecast period. The growth of the hepatitis test solution/diagnosis market in this region is driven by the widespread prevalence of hepatitis infections, increased healthcare spending by a larger population base, and modernization of healthcare infrastructure.

Nucleic Acid Tests (NATs) are relatively more expensive hepatitis diagnostic techniques than ELISA tests as the cost of NAT instruments is higher, in terms of outright purchases as well as rental agreements. NAT instruments require heavy investments, which most blood banks cannot afford. As a result, most end users opt for ELISA (serology) testing for hepatitis diagnosis, which limits the growth of the hepatitis testing market to a certain extent.

The key players in the hepatitis test solution/diagnosis market are Roche (Switzerland), Abbott Laboratories (US), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), Danaher (US), bioMérieux (France), and Grifols (Spain).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 13)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Years Covered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 16)
    2.1 Primary Data
           2.1.1 Key Data From Primary Sources
           2.1.2 Key Industry Insights
    2.2 Secondary Data
    2.3 Key Data From Secondary Sources
    2.4 Market Size Estimation
    2.5 Market Breakdown and Data Triangulation
           2.5.1 Assumptions for the Study

3 Executive Summary (Page No. - 24)

4 Premium Insights (Page No. - 27)
    4.1 Hepatitis Testing: Market Overview
    4.2 Geographic Analysis: Hepatitis Testing Market, By Disease Type (2018)
    4.3 Hepatitis Testing Market, By Technology, 2018 vs 2023
    4.4 Hepatitis Testing Market, By End User, 2016–2023

5 Market Overview (Page No. - 30)
    5.1 Introduction
           5.1.1 Drivers
                    5.1.1.1 High Burden of Hepatitis
                    5.1.1.2 Increasing Blood Transfusion and Donations
                    5.1.1.3 Benefits of POC Instruments & Kits
                    5.1.1.4 Awareness Initiatives
           5.1.2 Restraints
                    5.1.2.1 High Cost of Nat
                    5.1.2.2 Lack of Mandate for Nat in Developing Countries
           5.1.3 Opportunities
                    5.1.3.1 Emerging Markets

6 Hepatitis Testing Market, By Disease Type (Page No. - 35)
    6.1 Introduction
    6.2 Hepatitis B (HBV)
    6.3 Hepatitis C (HCV)
    6.4 Other Hepatitis Diseases

7 Hepatitis Testing Market, By Technology (Page No. - 41)
    7.1 Introduction
    7.2 Enzyme-Linked Immunosorbent Assay (ELISA)
    7.3 Rapid Diagnostic Tests (RDT)
    7.4 Polymerase Chain Reaction (PCR)
    7.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
    7.6 Other Technologies

8 Hepatitis Testing Market, By End User (Page No. - 50)
    8.1 Introduction
    8.2 Hospital & Diagnostic Laboratories
    8.3 Blood Banks
    8.4 Other End Users

9 Hepatitis Testing Market, By Region (Page No. - 56)
    9.1 Introduction
    9.2 North America
           9.2.1 US
           9.2.2 Canada
    9.3 Europe
           9.3.1 Germany
           9.3.2 UK
           9.3.3 Rest of Europe
    9.4 Asia Pacific
    9.5 Rest of the World

10 Competitive Landscape (Page No. - 76)
     10.1 Market Overview
     10.2 Market Ranking Analysis, 2017
     10.3 Competitive Situation and Trends
             10.3.1 Collaborations, Agreements, and Partnerships
             10.3.2 Product Launches and Approvals
             10.3.3 Acquisitions

11 Company Profiles (Page No. - 80)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
     11.1 Abbott Laboratories, Inc.
     11.2 Roche Diagnostics
     11.3 Bio-Rad Laboratories
     11.4 Siemens Healthineers
     11.5 Diasorin
     11.6 Qiagen
     11.7 Danaher Corporation
     11.8 Grifols
     11.9 Biomérieux Sa
     11.10 Ortho Clinical Diagnostics (A Part of the Carlyle Group)
     11.11 Fujirebio, Inc. (A Part of Miraca Group)

*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 105)
     12.1 Insights of Industry Experts
     12.2 Discussion Guide
     12.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     12.4 Available Customizations
     12.5 Related Reports
     12.6 Author Details


List of Tables (69 Tables)

Table 1 Global Hepatitis Prevalence (Million People Approx.), 2015
Table 2 Increase in Voluntary Non-Remunerated Blood Donations and Total Blood Donations, 2008–2013
Table 3 Hepatitis Testing Market, By Disease Type, 2016–2023 (USD Million)
Table 4 Hepatitis B Testing Market, By Region, 2016–2023 (USD Million)
Table 5 North America: Hepatitis B Testing Market, By Country, 2016–2023 (USD Million)
Table 6 Hepatitis C Testing Market, By Region, 2016–2023 (USD Million)
Table 7 North America: Hepatitis C Testing Market, By Country, 2016–2023 (USD Million)
Table 8 Hepatitis Testing Market for Other Diseases, By Region, 2016–2023 (USD Million)
Table 9 North America: Hepatitis Testing Market for Other Diseases, By Country, 2016–2023 (USD Million)
Table 10 Hepatitis Testing Market, By Technology, 2016–2023 (USD Million)
Table 11 Hepatitis Testing Market for ELISA, By Region, 2016–2023 (USD Million)
Table 12 North America: Hepatitis Testing Market for ELISA, By Country, 2016–2023 (USD Million)
Table 13 Europe: Hepatitis Testing Market for ELISA, By Country, 2016–2023 (USD Million)
Table 14 Hepatitis Testing Market for Rapid Diagnostic Tests, By Region, 2016–2023 (USD Million)
Table 15 North America: Hepatitis Testing Market for Rapid Diagnostic Tests, By Country, 2016–2023 (USD Million)
Table 16 Europe: Hepatitis Testing Market for Rapid Diagnostic Tests, By Country, 2016–2023 (USD Million)
Table 17 Hepatitis Testing Market for PCR, By Region, 2016–2023 (USD Million)
Table 18 North America: Hepatitis Testing Market for PCR, By Country, 2016–2023 (USD Million)
Table 19 Europe: Hepatitis Testing Market for PCR, By Country, 2016–2023 (USD Million)
Table 20 Hepatitis Testing Market for Inaat, By Region, 2016–2023 (USD Million)
Table 21 North America: Hepatitis Testing Market for Inaat, By Country, 2016–2023 (USD Million)
Table 22 Europe: Hepatitis Testing Market for Inaat, By Country, 2016–2023 (USD Million)
Table 23 Hepatitis Testing Market for Other Technologies, By Region, 2016–2023 (USD Million)
Table 24 North America: Hepatitis Testing Market for Other Technologies, By Country, 2016–2023 (USD Million)
Table 25 Europe: Hepatitis Testing Market for Other Technologies, By Country, 2016–2023 (USD Million)
Table 26 Hepatitis Testing Market, By End User, 2016-2023 (USD Million)
Table 27 Hepatitis Testing Market for Hospital & Diagnostic Labs, By Region, 2016–2023 (USD Million)
Table 28 North America: Hepatitis Testing Market for Hospital & Diagnostic Labs, By Country, 2016–2023 (USD Million)
Table 29 Europe: Hepatitis Testing Market for Hospital & Diagnostic Labs, By Country, 2016–2023 (USD Million)
Table 30 Hepatitis Testing Market for Blood Banks, By Region, 2016–2023 (USD Million)
Table 31 North America: Hepatitis Testing Market for Blood Banks, By Country, 2016–2023 (USD Million)
Table 32 Europe: Hepatitis Testing Market for Blood Banks, By Country, 2016–2023 (USD Million)
Table 33 Hepatitis Testing Market for Other End Users, By Region, 2016–2023 (USD Million)
Table 34 North America: Hepatitis Testing Market for Other End Users, By Country, 2016–2023 (USD Million)
Table 35 Europe: Hepatitis Testing Market for Other End Users, By Country, 2016–2023 (USD Million)
Table 36 Hepatitis Testing Market, By Region, 2016–2023 (USD Million)
Table 37 North America: Hepatitis Testing Market, By Country, 2016–2023 (USD Million)
Table 38 North America: Hepatitis Testing Market, By Disease Type, 2016–2023 (USD Million)
Table 39 North America: Hepatitis Testing Market, By Technology, 2016–2023 (USD Million)
Table 40 North America: Hepatitis Testing Market, By End User, 2016–2023 (USD Million)
Table 41 HAV and HBV Vaccination Coverage: US (2014–2016)
Table 42 US: Hepatitis Testing Market, By Disease Type, 2016–2023 (USD Million)
Table 43 US: Hepatitis Testing Market, By Technology, 2016–2023 (USD Million)
Table 44 US: Hepatitis Testing Market, By End User, 2016–2023 (USD Million)
Table 45 Canada: Hepatitis Testing Market, By Disease Type, 2016–2023 (USD Million)
Table 46 Canada: Hepatitis Testing Market, By Technology, 2016–2023 (USD Million)
Table 47 Canada: Hepatitis Testing Market, By End User, 2016–2023 (USD Million)
Table 48 Europe: Hepatitis Testing Market, By Country, 2016–2023 (USD Million)
Table 49 Europe: Hepatitis Testing Market, By Disease Type, 2016–2023 (USD Million)
Table 50 Europe: Hepatitis Testing Market, By Technology, 2016–2023 (USD Million)
Table 51 Europe: Hepatitis Testing Market, By End User, 2016–2023 (USD Million)
Table 52 Germany: Hepatitis Testing Market, By Technology, 2016–2023 (USD Million)
Table 53 Germany: Hepatitis Testing Market, By End User, 2016–2023 (USD Million)
Table 54 UK: Hepatitis Testing Market, By Technology, 2016–2023 (USD Million)
Table 55 UK: Hepatitis Testing Market, By End User, 2016–2023 (USD Million)
Table 56 RoE: Hepatitis Testing Market, By Technology, 2016–2023 (USD Million)
Table 57 RoE: Hepatitis Testing Market, By End User, 2016–2023 (USD Million)
Table 58 Estimated Prevalence of Chronic HBV and HCV: Asia Pacific
Table 59 Asia-Pacific: Cost Coverage for Diagnosis of Chronic Viral Hepatitis
Table 60 APAC: Hepatitis Testing Market, By Disease Type, 2016–2023 (USD Million)
Table 61 APAC: Hepatitis Testing Market, By Technology, 2016–2023 (USD Million)
Table 62 APAC: Hepatitis Testing Market, By End User, 2016–2023 (USD Million)
Table 63 RoW: Hepatitis Testing Market, By Disease Type, 2016–2023 (USD Million)
Table 64 RoW: Hepatitis Testing Market, By Technology, 2016–2023 (USD Million)
Table 65 RoW: Hepatitis Testing Market, By End User, 2016–2023 (USD Million)
Table 66 Rank of Companies in the Hepatitis Testing Market, 2017
Table 67 Collaborations, Agreements, and Partnerships
Table 68 Product Launches and Approvals, 2015–2018
Table 69 Acquisitions, 2015-2018


List of Figures (29 Figures)

Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Data Triangulation
Figure 6 Hepatitis Testing Market, By Disease Type, 2018 vs 2023
Figure 7 Hepatitis Testing Market, By Technology, 2018 vs 2023
Figure 8 Hepatitis Testing Market, By End User, 2018 vs 2023
Figure 9 Geographical Snapshot of the Hepatitis Testing Market
Figure 10 High Burden of Hepatitis & Initiatives Taken By Government and Non-Government Organizations—Key Factors Driving Market Growth
Figure 11 Hepatitis B Segment to Account for the Largest Market Share in 2018
Figure 12 ELISA Will Continue to Dominate the Hepatitis Testing Market, By Technology, in 2023
Figure 13 Hospital & Diagnostic Laboratories to Account for the Largest Market Share in 2018
Figure 14 Hepatitis Testing Market: Drivers, Restraints, and Opportunities
Figure 15 Hepatitis Testing Market: Geographic Snapshot (2018)
Figure 16 North America: Market Snapshot
Figure 17 Reported Acute (New) Cases of Hepatitis C: US (2010-2016)
Figure 18 Asia Pacific: Hepatitis Testing Market Snapshot
Figure 19 Key Developments in the Hepatitis Testing Market Between 2015 and 2017
Figure 20 Abbott: Company Snapshot (2017)
Figure 21 Roche Diagnostics: Company Snapshot (2017)
Figure 22 Bio-Rad: Company Snapshot (2017)
Figure 23 Siemens AG: Company Snapshot (2017)
Figure 24 Diasorin: Company Snapshot (2017)
Figure 25 Qiagen: Company Snapshot (2017)
Figure 26 Danaher: Company Snapshot (2017)
Figure 27 Grifols: Company Snapshot (2017)
Figure 28 Biomérieux: Company Snapshot (2017)
Figure 29 Miraca: Company Snapshot (2017)


Request for detailed methodology, assumptions & how numbers were triangulated.

Our USP is "Customised multi client reports"-so feel free to provide us specific interest in much greater detail..!!
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
MD 6643
Published ON
Oct, 2018
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Hepatitis Test Solution/Diagnosis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved